A Match Made in Cancer—Fickle Kinases, Promiscuous Drugs

September 1, 2015
A Match Made in Cancer—Fickle Kinases, Promiscuous Drugs
Source: iStock/© evryka23

The genetic basis of a patient’s cancer is often unclear. A patient’s cancer may be driven by just one out of many possible genetic causes, or it may be the culmination of multiple genetic causes. All of these possibilities exist in a kind of cloud, which is complemented by another sort of cloud, which consists of the various cancer-suppression activities that one drug, or a combination of drugs, may have. Some drugs are “promiscuous.” For example, some cancer drugs inhibit multiple cancer-related kinases.

A patient’s cancer-driver cloud might overlap with a particular drug’s cancer-suppression cloud, but who could say? We’re dealing with clouds, after all, not the crisply bound regions we see in Venn diagrams.

For the rest of the story, click here.


Oops! Please type your email in the following format: [email protected]

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly